BioCentury on BioBusiness,
Ebb & Flow
Monday, October 15, 2001
Isis filed for a 5 million share follow-on, but market watchers don't believe it marks the start of an underwritten funding window. Rather, the company is selling into strength of its stock price in the wake of its antisense deal with Eli Lilly (LLY) for metabolic and inflammatory diseases, in which LLY promised to pay ISIP north of $300 million (see BioCentury, Aug. 27). The stock is up $9.22 since the announcement, so even if it gets the typical 15% road show haircut, the shares still should be well above its pre-deal price of $10.08.
ISIP helped its own cause last Wednesday, when it moved up $0.94 to $18.92 on 876,600 shares on news that its
ISIS 2302 inhibitor of ICAM-1 improved symptoms of active distal ulcerative colitis (UC) in a European Phase II trial (see B13).
The company would raise $96.5 million if the deal goes off at Friday's close of $19.30. UBS Warburg is the lead manager. Robertson Stephens; Needham; and Fortis Securities are co-managers.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]